Oncostellae is a biotech startup developing small-molecule drugs with innovative scaffolds (NCEs) that modulate clinically validated therapeutic targets in oncology and inflammatory/autoimmune diseases.
The company was founded in 2013 by a team of medicinal chemists and pharmacologists with a common track record in drug discovery who bring together the experience and network of collaborators to develop clinical candidates from their conception until Phase I/II. Further development and commercialization rights will be licensed to consolidated pharmaceutical companies.
In 2014 Guido Kurz, a seasoned research manager with international trajectory in various pharmaceutical and biotech companies (including Pharmacia Corp. and Oryzon Genomics), joined Oncostellae as CEO of the company.
In 2019 Ramon Bosser joined the company as Clinical Director. Ramon has 20+ years of experience in drug development from research to clinical development in pharma and biotech companies (including Almirall and Spherium Biomed), where he had leading roles from project management to C-level.
In 2020 Ascensión Heredia joined Oncostellae as Chief Operating Officer. Ascension has an extensive experience in pharmaceutical industry (Big Pharma and Biotech Companies) leading projects in idea generation, drug discovery and drug development from preclinical phases till Phase IV including small molecules and biologics and advanced therapies. Since 1992, she has worked in national and international companies such as Almirall, Advancell, Bionure, Mosaic Biomedicals and Northern Biologics, where she has held roles from project manager to C-level positions.